NCT03717844
- Conditions
- Abnormalities, Multiple, Amyloidosis, Blood Protein Disorders, +40 more
- Locations
-
- North Carolina Cancer Hospital Chapel Hill, North Carolina, United States
Clinical trial condition
Lymphoproliferative Disorders
Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.
10,146 public trials
2,034 recruiting studies
Lymphoproliferative Disorders trial results
Recruiting
A Cohort Study in Newly Diagnosed MZL
NCT06449885
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
Recruiting
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
NCT07233720
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university Zhengzhou, Henan, China
NCT06530576
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China
NCT07188077
- Conditions
- Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
- Locations
-
- The First Affiliated Hospital of Fujian Medical University Fuzhou, Fujian, China
NCT04510766
- Conditions
- Advanced Solid Tumor, Hemic and Lymphatic Diseases, Immune System Diseases, +6 more
- Locations
-
- Oncology Institute of Southern Switzerland Bellinzona, Switzerland
NCT07180992
- Conditions
- Blood Protein Disorders, CART Cells, Cardiovascular Diseases, +14 more
- Locations
-
- CHRU Amiens Amiens, France
NCT07198230
- Conditions
- Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +15 more
- Locations
-
- The First Affiliated Hospital of Fujian Medical University Fuzhou, Fujian, China
Recruiting
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06716658
- Conditions
- Cutaneous T Cell Lymphoma, Cutaneous T Cell Lymphoma (CTCL), Hematologic Diseases, +22 more
- Locations
-
- Institute of Hematology & Blood Diseases Hospital, China Tianjin, Tianjin Municipality, China
- Institute of Hematology & Blood Diseases Hospital Tianjin, China
NCT07053670
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology Wuhang, Hubei, China